All Updates

All Updates

icon
Filter
M&A
Tryp Therapeutics mergers with Exopharm; renames to Tryptamine Therapeutics
Psychedelic Medicine
Apr 24, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Apr 24, 2024

Tryp Therapeutics mergers with Exopharm; renames to Tryptamine Therapeutics

M&A

  • Canadian clinical-stage pharmaceutical company Tryp Therapeutics has received shareholder approval to merge with Exopharm and operate under a combined entity. In December 2023 , Exopharm entered a definitive agreement to acquire all outstanding shares of Tryp Therapeutics. The transaction is to close by May 1, 2024, subject to conditions.

  • After the merger, Tryp intends to continue advancing its pipeline of psilocin-based therapies. The merger is expected to provide the company with increased visibility and access to a more extensive investor base. 

  • Furthermore, the merged entity will be known as "Tryptamine Therapeutics Limited" and will commence trading on the Australian Securities Exchange under the ticker symbol "TYP" from May 15, 2024, subject to necessary approvals and conditions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.